Stark M - Search Results

1

Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma.

Doecke J, Zhao ZZ, Pandeya N, Sadeghi S, Stark M, Green AC, Hayward NK, Webb PM, Whiteman DC; Australian Cancer Study. Doecke J, et al. Among authors: stark m. Int J Cancer. 2008 Jul 1;123(1):174-80. doi: 10.1002/ijc.23410. Int J Cancer. 2008. PMID: 18386788 Free article.

2

Mutation analysis of the CDKN2A promoter in Australian melanoma families.

Pollock PM, Stark MS, Palmer JM, Walters MK, Aitken JF, Martin NG, Hayward NK. Pollock PM, et al. Among authors: stark ms. Genes Chromosomes Cancer. 2001 Sep;32(1):89-94. doi: 10.1002/gcc.1170. Genes Chromosomes Cancer. 2001. PMID: 11477665

3

MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations.

Box NF, Duffy DL, Chen W, Stark M, Martin NG, Sturm RA, Hayward NK. Box NF, et al. Among authors: stark m. Am J Hum Genet. 2001 Oct;69(4):765-73. doi: 10.1086/323412. Epub 2001 Aug 8. Am J Hum Genet. 2001. PMID: 11500805 Free PMC article.

4

Ocular melanoma is not associated with CDKN2A or MC1R variants--a population-based study.

Vajdic C, Kricker A, Duffy DL, Aitken JF, Stark M, ter Huurne JA, Martin NG, Armstrong BK, Hayward NK. Vajdic C, et al. Among authors: stark m. Melanoma Res. 2003 Aug;13(4):409-13. doi: 10.1097/00008390-200308000-00011. Melanoma Res. 2003. PMID: 12883368

5

Microarray expression profiling in melanoma reveals a BRAF mutation signature.

Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, Walker GJ, Boyle GM, Harper U, Cozzi SJ, Hansen K, Yudt L, Schmidt C, Hersey P, Ellem KA, O'Rourke MG, Parsons PG, Meltzer P, Ringnér M, Hayward NK. Pavey S, et al. Among authors: stark m. Oncogene. 2004 May 20;23(23):4060-7. doi: 10.1038/sj.onc.1207563. Oncogene. 2004. PMID: 15048078

6

Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues.

Biondi CA, Gartside MG, Waring P, Loffler KA, Stark MS, Magnuson MA, Kay GF, Hayward NK. Biondi CA, et al. Mol Cell Biol. 2004 Apr;24(8):3125-31. doi: 10.1128/MCB.24.8.3125-3131.2004. Mol Cell Biol. 2004. PMID: 15060136 Free PMC article.

7

Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.

Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, Packer L, Borgstein AM, Pavey S, van der Velden P, Out C, Jager MJ, Hayward NK, Gruis NA. Zuidervaart W, et al. Among authors: stark m. Br J Cancer. 2005 Jun 6;92(11):2032-8. doi: 10.1038/sj.bjc.6602598. Br J Cancer. 2005. PMID: 15928660 Free PMC article.

8

BRAF polymorphisms and risk of melanocytic neoplasia.

James MR, Roth RB, Shi MM, Kammerer S, Nelson MR, Stark MS, Dumenil T, Montgomery GW, Hayward NK, Martin NG, Braun A, Duffy DL. James MR, et al. Among authors: stark ms. J Invest Dermatol. 2005 Dec;125(6):1252-8. doi: 10.1111/j.0022-202X.2005.23937.x. J Invest Dermatol. 2005. PMID: 16354196 Free article.

9

Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.

Packer L, Pavey S, Parker A, Stark M, Johansson P, Clarke B, Pollock P, Ringner M, Hayward N. Packer L, et al. Among authors: stark m. Carcinogenesis. 2006 Sep;27(9):1778-86. doi: 10.1093/carcin/bgl016. Epub 2006 Mar 29. Carcinogenesis. 2006. PMID: 16571650

10

PI3-kinase subunits are infrequent somatic targets in melanoma.

Curtin JA, Stark MS, Pinkel D, Hayward NK, Bastian BC. Curtin JA, et al. J Invest Dermatol. 2006 Jul;126(7):1660-3. doi: 10.1038/sj.jid.5700311. Epub 2006 Apr 13. J Invest Dermatol. 2006. PMID: 16614723 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,156 results

Search Page